Skip to content
HealthTech Seed Founded 2020

Eleven

Eleven harnesses combinatorial chemistry and AI to transform RNAi drug development into a programmable process, targeting diseases including influenza and SARS-CoV-2. Founded in 2020 in Cambridge, United Kingdom, the company has raised $22.0M in seed funding from investors including Gates, Kindred Capital, and Entree Capital. AI-based RNA drug development platform for researchers. The company harnesses the power of…

📍 Cambridge, United Kingdom · Life Sciences Tech,

Funding snapshot

Last roundSeed
Amount$3M
Date17 April 2025
Total raised$22M
Team size17

About

Eleven harnesses combinatorial chemistry and AI to transform RNAi drug development into a programmable process, targeting diseases including influenza and SARS-CoV-2. Founded in 2020 in Cambridge, United Kingdom, the company has raised $22.0M in seed funding from investors including Gates, Kindred Capital, and Entree Capital. AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2. Founded in 2020, headquartered in Cambridge, United Kingdom. The team comprises 17 (Jun 30, 2026) employees. Backed by investors including Gates, Kindred Capital, Entree Capital, Harel Group. The company is tagged with Te.

Business model

Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Drug Development,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Team background

College Wise > Tel Aviv University

Institutional investors

Gates Kindred Capital Entree Capital Harel Group Gov NFX HHS

Latest coverage

No articles yet.

Raising like Eleven?

Analyze your pitch deck before your next raise.

Analyze My Deck →